As tumors grow, they acquire mutations, some of which create neoantigens that influence
the response of patients to immune checkpoint inhibitors. We explored the impact of …

Background Among patients with non–small-cell lung cancer (NSCLC), data on intratumor
heterogeneity and cancer genome evolution have been limited to small retrospective cohorts. …

The early detection of relapse following primary surgery for non-small-cell lung cancer and
the characterization of emerging subclones, which seed metastatic sites, might offer new …

Immune evasion is a hallmark of cancer. Losing the ability to present neoantigens through
human leukocyte antigen (HLA) loss may facilitate immune evasion. However, the …

The interplay between an evolving cancer and a dynamic immune microenvironment remains
unclear. Here we analyse 258 regions from 88 early-stage, untreated non-small-cell lung …

The evolutionary features of clear-cell renal cell carcinoma (ccRCC) have not been systematically
studied to date. We analyzed 1,206 primary tumor regions from 101 patients recruited …

Lung cancer is the leading cause of cancer-associated mortality worldwide 1 . Here we
analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients …

B cells are frequently found in the margins of solid tumours as organized follicles in ectopic
lymphoid organs called tertiary lymphoid structures (TLS) 1 , 2 . Although TLS have been …

A widespread approach to modern cancer therapy is to identify a single oncogenic driver
gene and target its mutant-protein product (for example, EGFR-inhibitor treatment in EGFR-…

Metastatic disease is responsible for the majority of cancer-related deaths 1 . We report the
longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from …